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The introduction of highly active antiretroviral therapies (HAART) has significantly 
changed the clinical course of HIV disease, with prolonged survival and better quality 
of life for HIV infected patients. However, this successful therapeutic advance has been 
partially marked by the development of serious long-term side effects including metabolic 
alterations, cardiovascular disease, kidney impairment, bone alterations and adipose tissue 
redistribution. This last phenomenon is currently indicated as HIV related lipodystrophy 
(Barbaro, 2006). Even if some studies suggested an independent role for HIV in the devel-
opment of lipodystrophic phenotype, there is a widely accepted consensus that the risk to 
develop fat redistribution in HIV patients has to be mostly related to antiretroviral therapy. 
In order to investigate new pathways involved in the development of lipodystrophy, 
our group performed an array screening using two identical filter arrays with cDNA-
labeled probes, generated from the adipose tissue of either HIV patients affected or 
not affected by lipodystrophy. Among the genes selected, we focused our attention on 
a recently described 48 kDa protein of 417 amino acids named FAP48. Our results sug-
gest, using 3T3-L1-FAP48 stable clone, that FAP48 over-expression results in rapid NFAT 
dephosphorilatyon by activating CaN and in the increase of aP2 gene transcription, a gene 
expressed at the last phase of the adipocyte differentiation. These data support the role of 
Fap48 in the activation of adipocyte differentiation through a pathway involving NFAT. 
Moreover we evaluated the expression of PPARγ and aP2 in 3T3-L1 FAP48pcDNA 
stably transfected cells treated with five antiretroviral drugs (Indinavir, Amprenavir, Efa-
virenz, Stavudine and Saquinavir), belonging to the three main classes of anti-HIV drugs, 
that were able, in our experimental model, to affect adipocyte differentiation (Esposito 
et al., 2009). We observed that cells treated with Saquinavir and Efavirenz, using 3T3-L1-
FAP48 stable clone, are characterized by an increased expression of PPARγ and aP2, dur-
ing the 6 day time course, compared with the control cells. This evidence supports the 
hypothesis of a protective mechanism, that in 3T3L1 cells could counteract the toxicity of 
Efavirenz and Saquinavir or could be activated in presence of these drugs. Drawing from 
our experimental results it can be then postulated that this mechanism could work trough 
FAP48/ FBP52/Hsp90 pathway, suggesting this complex as a potential target for novel 
therapeutic approaches to the HAART related lipodystrophy in patients treated with regi-
men including Efavirenz and Saquinavir. 
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